RNS Number : 1846L
Genedrive PLC
11 December 2025

genedrive plc
("genedrive" or the "Company")

genedrive plc launches new interactive investor hub

genedrive plc (LSE: GDR), the point of care pharmacogenetic testing company, is pleased to announce the launch of our interactive investor hub. For both existing and prospective shareholders, over time the new investor hub will bring all genedrive content into a single integrated platform to better inform and engage with investors and stakeholders.

The investor hub provides an interactive online experience allowing genedrive stakeholders to comment on and ask the genedrive team questions via a portal which will be monitored and responded to as timely as possible.

How to sign up for the genedrive investor hub:

1. Visit investors.genedrive.com
2. Follow the prompts to sign up for an investor hub account
3. Complete your account profile

Dr Gino Miele, CEO of genedrive plc, said: *"Open and transparent communication with our shareholders is essential, particularly in a fast-moving environment like ours. Whilst RNS remains the first source of regulated news on genedrive, the investor hub gives us a direct channel to share accurate information and meaningful updates straight from the company ensuring investors hear from us directly. The hub enables shareholders to submit questions, receive updates, and engage directly with the Company. We encourage all investors to register and use the hub as their central source for trusted updates, insights, and dialogue with our team."*

Engage with the genedrive management team directly by asking questions, watching video summaries and seeing what other shareholders have to say. Navigate to our Interactive Investor hub here: https://investors.genedrive.com/link/PZ3d7y

For further information, please contact:

Genedrive plc https://investors.genedrive.com/s/e0025c
Dr Gino Miele (CEO) +44 (0) 161 989 0245
Russ Shaw (CFO)

We encourage all investors to share questions on this announcement via our investor hub

+44 (0) 20 7148 8900

Peel Hunt LLP - Nominated Adviser, Joint Broker
James Steel

Walbrook PR Ltd (Media & Investor Relations) https://investors.genedrive.com/s/e0025c
Anna Dunphy +44 (0)20 7933 8780 or genedrive@walbrookpr.com
+44 (0)7876 741 001

Subscribe to our news alert service: https://investors.genedrive.com/s/efea03

About genedrive plc (http://www.genedrive.com)

About genedrive plc (http://www.genedrive.com)

genedrive plc is a pharmacogenetic testing company developing and commercialising a low cost, rapid, versatile and simple to use point of need pharmacogenetic platform for the diagnosis of genetic variants. This helps clinicians to quickly access key genetic information that will aid them make the right choices over the right medicine or dosage to use for an effective treatment, particularly important in time-critical emergency care healthcare paradigms. Based in the UK, the Company is at the forefront of Point of Care pharmacogenetic testing in emergency healthcare. Pharmacogenetics informs on how your individual genetics impact a medicines ability to work for you. Therefore, by using pharmacogenetics, medicine choices can be personalised, made safer and more effective. The Company has launched its two flagship products, the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit, both developed and validated in collaboration with NHS partners and deployed on its point of care thermocycler platform. Both tests are single-use disposable cartridges which are ambient temperature stable, circumventing the requirement for cold chain logistics. The Directors believe the Genedrive® MT-RNR1 ID Kit is a worlds-first and allows clinicians to make a decision on antibiotic use in neonatal intensive care units within 26 minutes, ensuring vital care is delivered, avoiding adverse effects potentially otherwise encountered and with no negative impact on the patient care pathway. Its CYP2C19 ID Kit which has no comparably positioned competitor currently allows clinicians to make a decision on the use of Clopidogrel in stroke patients in 70 minutes, ensuring that patients who are unlikely to benefit from or suffer adverse effects from Clopidogrel receive an alternative antiplatelet therapeutic in a timely manner, ultimately improving outcomes. Both tests have undergone review by the National Institute for Health and Care Clinical Excellence ("NICE") and have been recommended for use in the UK NHS. The Company has a clear commercial strategy focused on accelerating growth through maximising in-market sales, geographic and portfolio expansion and strategic M&A, and operates out of its facilities in Manchester.

END

MSCUAUWRVBUUARA